Moderna, Inc.
(NASDAQ: MRNA)
Balfour Capital Group has issued a buy recommendation
for Moderna, Inc. (MRNA) on October 1st, 2024
In 2023, Moderna’s total revenue was reported at $6.8 billion, a decline from the $19.3
billion earned in 2022, primarily due to reduced sales of its COVID-19 vaccine. The
company anticipates revenue of around $4 billion for 2024. In 2024, Moderna is focused
on its respiratory franchise, including the development of vaccines for seasonal flu and
RSV (Respiratory Syncytial Virus) and its next-generation COVID-19 vaccine.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $63.93 on October 1st, 2024.
- Our designated price target stands at $80.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Moderna, Inc. (NASDAQ: MRNA)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
